公司简介
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ...
关联新闻
- EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.
Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.
- EyePoint's eye drug misses main goal in late-stage trial
EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.